New clinical trial, HIV Vacc-4x in combination with Revlimid® (Lenalidomide)
Oslo – 25.08.11 – Bionor Pharma ASA Announces Exploratory Study of its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination with Leading Cancer Drug The study will determine: The target patient population for the study will be HIV-patients whose immune system have not fully recovered (defined by CD4+ (helper) T-cell count in the interval 250-400 cells …